|
Of course I don't mind...that is why we are here...:)
Tricia,
I would love to read the article or send me a link.
Dr. Slamon explained it that TOPO 11 negative would not receive benefit
from A/C and along with herceptin may have unnecessary risk for heart damage. He recommended chemo - but TCH and the trial results were
excellant with this treamtent. I have not heard that the TCH would not
be as responsive to TOPO 11 negative. I did go forward with the TCH
treatment as he advised. Will give him a ring and ask him
about this. I have heard that HER2 positive in general can be resistive to
chemo - that was the driving force for Dr. Slamon with the development of hercetpin.
If you can send the article or link it I will forward it to him also.
Kind Regards,
Jean
__________________
Stage 1, Grade 1, 3/30/05
Lumpectomy 4/15/05 - 6MM IDC
Node Neg. (Sentinel node)
ER+ 90% / PR-, Her2+++ by FISH
Ki-67 40%
Arimidex 5/05
Radiation 32 trt, 5/30/05
Oncotype DX test 4/17/06, 31% high risk
TOPO 11 neg. 4/06
Stopped Arimidex 5/06
TCH 5/06, 6 treatments
Herceptin 5/06 - for 1 yr.
9/06 Completed chemo
Started Femara Sept. 2006
|